Changing the World
with Disruptive Companies

Backing technologies solving our world’s biggest challenges. Our latest funds invest in deep tech start-ups in healthcare, biotechnology, renewable energy, nanotechnology and artificial intelligence.

Our Sectors

Energy
Edit the text by double-clicking.
Financials
Edit the text by double-clicking.
Materials
Edit the text by double-clicking.
I.T
Edit the text by double-clicking.
Healthcare
Edit the text by double-clicking.
OUR CHANGEMAKERS
AWAK
Ultra-portable and wearable kidney dialysis machines

AWAK is a patient-centric medical technology company with a mission to enhance the lives of people with kidney disease and their caregivers by providing solutions to deliver better outcomes along with improving their quality of life.

AWAK sorbent technology is a platform technology that has the ability to revolutionize both peritoneal dialysis and haemodialysis, as it’s enabling development of ultra-portable PD (Peritoneal Dialysis) & HD (Haemodialysis) machines. This technology enables a significant reduction in the amount of fresh dialysate required per therapy. AWAK PD can be controlled via a mobile application and is digitally connected with a web portal at the clinician’s side, which enables them to remotely manage their patients’ therapy and monitor their health, ensuring complete care management. AWAK HD sorbent will lead to significant reduction of HD dialysate needed from 120L to 4L, and will enable moving HD from in-centre to at-home
TEAM MEMBERS
Suresha Venkataraya, Chief Executive Officer
This is some text inside of a div block.

Vickers shares our vision for bringing disruptive innovation to kidney care and has been an exceptional partner throughout our journey of taking our product to the next phase of the clinical trials.

Having Vickers as our shareholders has been one of the best things to happen to AWAK in the last three years. Prior to Vickers investing, the team invested a significant amount of time to fully understand our market and product, which proved critical in securing an oversubscribed investment round. Vickers shares our vision for bringing disruptive innovation to kidney care and has been an exceptional partner throughout our journey of taking our product to the next phase of the clinical trials.

Jeff and Finian from Vickers have played instrumental roles in our success, leveraging their extensive experience and knowledge of the start-up world. We are fortunate to have tapped into Vickers' network of investors, and their support has been invaluable in raising subsequent rounds of financing.

Moreover, the US-based members of Vickers' team, especially Mhamed and Xinhong, have been exceptional in providing us with market intelligence and acting as our ambassadors in the US. This is particularly important for us, as the US market is a key market for our product.

Vickers has been extremely supportive of our senior management team, acting as an extended team member with whom we can have candid conversations at any time. We attribute a significant part of our success and progress to Vickers' involvement.

—Suresh Venkataraya, CEO, AWAK

Aardvark
Harnessing the body's homeostatic pathways to treat diseases

Aardvark Therapeutics is San Diego based pharmaceutical company specializing in gut brain interaction with a focus of inflammation and metabolism.

Aardvark Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics that activate innate homeostatic pathways for the treatment of disease. Their lead product, ARD-101, is a first-in-class oral composition that is gut restricted, yet conveys systemic effects via activation of gut peptide hormone secretion. Preclinical data demonstrate safety as well as efficacy in a number of metabolic and inflammatory disease models.
TEAM MEMBERS
Tien Lee, M.D., Chief Executive Officer
This is some text inside of a div block.

As a founder, it has been refreshing to engage with an investor that is creative, nimble, responsive, and constructive in the growth of the company with the flexibility to recognize new opportunities when they manifest.

Aardvark Therapeutics has been developing as its lead program, ARD-101, a first-in-class therapeutic with a novel mechanism of action. Early on, the Vickers team demonstrated a deep understanding of the scientific rationale and recognized the profound opportunity represented when it was less apparent to others. Aardvark has since made significant progress over a relatively short period of time in no small part due to the valued support from Vickers throughout the process. Beyond the initial lead program, company has now created a broad pipeline of additional promising therapeutics, and this expansion was facilitated by the vision and measured support of multiple members of the Vickers team.

As a founder, it has been refreshing to engage with an investor that is creative, nimble, responsive, and constructive in the growth of the company with the flexibility to recognize new opportunities when they manifest. Jeff Chi has been a most valued board member that has thoughtfully contributed to the strategic planning for the company and Vickers analysts have frequently contributed with scientific and competitive insights as well as facilitating networking opportunities.

— Dr Tien Lee, CEO, Aardvark Therapeutics

Atomwise
AI drug discovery engine to make better medicines faster

Atomwise is a technology-enabled pharmaceutical company leveraging the power of AI to revolutionize small molecule drug discovery.

The Atomwise team invented the use of deep learning for structure-based drug design; this technology underpins Atomwise’s best-in-class AI discovery engine, which is differentiated by its ability to find and optimize novel chemical matter. Atomwise has extensively validated its discovery engine, delivering success in over 185 projects to-date including a wide-variety of protein types and numerous “hard-to-drug” targets. Atomwise is building a wholly-owned pipeline of small-molecule drug candidates, with three programs in lead-optimization and over 30 programs in discovery.
TEAM MEMBERS
Abraham Heifets PhD, CEO, Co-founder
This is some text inside of a div block.
Chooch
Scalable Computer Vision platform for Enterprise Applications

Chooch creates and deploys the world’s best Visual AI applications that are powerful, ingenious and trustworthy, to make lives better.

Chooch is the only AI computer vision platform that instantly detects specific visuals, objects, and actions in video images, including critical anomalies. It immediately comprehends their significance and launches preprogrammed responses – all in a fraction of the time it takes the human eye to notice an issue. Chooch services multiple industries – manufacturing, public sector, retail, telco, healthcare and many more across fortune 500 companies with leading partner including Microsoft, Deloitte, Nvidia, EY and HPE.
TEAM MEMBERS
Emrah Gultekin, CEO
Anubhav Saxena, President & COO
Hakan Gultekin, CTO
This is some text inside of a div block.

Vickers was our first institutional investor - a testament to willingly do objective diligence and make first bets based on a combination of complex variables.

Vickers was our first institutional investor - a testament to willingly do objective diligence and make first bets based on a combination of complex variables.  We are incredibly fortunate to have Finian and his team’s hands-on support throughout our journey.

Eavor
Scalable clean energy for baseload, dispatchable power anywhere in the world with geothermal

Eavor is a clean energy company focused on advanced geothermal and led by a team dedicated to creating a clean, reliable and affordable energy future on a global scale.

Eavor’s solution (Eavor-Loop™) represents the world’s first truly scalable form of clean, baseload and dispatchable power. Eavor achieves this by mitigating or eliminating many of the issues that have hindered traditional geothermal solutions. As a completely closed-loop system, Eavor has the advantage of having no fracking, no GHG emissions, no earthquake risk, no water use, no produced brine or solids, and no aquifer contamination. Eavor instead circulates a benign working fluid which is completely isolated from the environment in a closed-loop, much like a massive subsurface radiator. This “radiator” simply collects heat from the natural geothermal gradient of the Earth via conduction, at geologically common and drilling accessible rock temperatures. Unlike traditional geothermal, Eavor isn’t burdened with exploratory risk or limited to niche geographies through the need for highly permeable aquifers at volcanic-like temperatures. Unlike wind and solar, Eavor-Loop™ is not intermittent, but instead produces much-needed reliable baseload power with far less of a surface footprint. Unlike other forms of power, Eavor is benign enough to literally fit in someone’s backyard.
TEAM MEMBERS
John Redfern, President & CEO
Neil Bothwell, Chief Financial Officer (interim)
Paul Cairns, Chief Business Development Officer
Matt Toews, Chief Technology Officer
Jeanine Vany, Executive Vice President / Geosciences
Robert Winsloe, Executive Vice President / Origination
This is some text inside of a div block.

It has been more like being part of a family, rather than as a mere investment as is often the case with other VCs. They are always in your corner, trying to grow the company for all.

The experience we have had with Vickers has been like no other. It has been more like being part of a family, rather than as a mere investment as is often the case with other VCs. They are always in your corner, trying to grow the company for all. In addition, the ongoing contributions of Finian, Khalil, Chris Ho, and many others, to our business have helped to both shape the direction and truly raise the value of our business.

There is a depth of experience at Vickers deployed to first listen, and then provide advice with an underlying presence of support. Their role on our Board of Directors has been invaluable, both Finian and Chris are an important touch point which our management team has come to rely upon.
 
– John Redfern & Paul Cairns – Founders, Eavor Technologies Inc.

Emergex
T-cell based vaccines to eradicate infectious diseases

Emergex is developing T-Cell Adaptive Vaccines against viral and bacterial infectious diseases, using purely synthetic non-biological components that prime immune cells to destroy pathogen-infected cells.

Most current vaccines are antibody-focused and have shown rapidly decreasing effectiveness against new viral variants. Emergex's range of 100% synthetic vaccines create broad, cross-protective, and durable immunity based on CD8+ T-cells that kill cells infected with viral strains and variants, without the problems associated with excessive inflammation or antibodies. Such T-cell immunity can last for almost 20 years and is increasingly recognized to protect against disease even in the absence of neutralizing antibodies. It can prevent sickness by inhibiting productive viral infection. Emergex works on addressing some of the world’s most immediate health threats (including viral diseases such as Dengue Fever, COVID-19, Zika, Ebola and pandemic Influenza, as well as serious intracellular bacterial infections) and has a growing pipeline of vaccine candidates. They have completed Phase I clinical trials in Switzerland with good safety and promising efficacy data, and are in the process of commencing Phase I and II trials in other countries.
TEAM MEMBERS
Professor Thomas Rademacher, Co-founder & CEO
Storme Moore-Thornicroft, Co-founder, Executive Director & COO
This is some text inside of a div block.
Entomo
Modern performance management software built for the ‘future of work'

entomo offers an end-to-end platform that enables ‘Enterprises of Tomorrow’ to perform, engage, act and grow.

entomo improves business performance by aligning people goals and generating insights from several data sources. The insights and action nudges are hyper-personalized to each user's goals. entomo also successfully developed the mobile application "MySejahtera" for the Government of Malaysia to facilitate contact tracing efforts in response to the COVID-19 pandemic.
TEAM MEMBERS
Ravee Ramamoothie. President, Group CEO and Founder
Naveen Deshpande, Co-Founder, Lead Technology & Product Executive
This is some text inside of a div block.

They bring in the domain knowledge and experience while offering guidance that is right for our organisation and to the problem at hand. The guidance officered is not just in strategy, but also in network, operations, and more, while ensuring the founding team has the freedom to make independent decisions.

Vickers has played a critical part in entomo’s success right from the outset. Vickers recognized the potential in our technology early on and has been a part of the journey ever since. Not only have they brought funding, but they have been a strategic partner and are involved in perfecting the vision, strategy, operations, and more.

The entire Vickers team, particularly Dr. Finian Tan and Dr Damian Tan as Chairman and Director of the board respectively have been an inspiration. Their mentorship has contributed immensely to the organization’s vision and strategy. Vickers’ branding has also helped entomo gain the trust of our customers and investors.

Vickers has been involved in key strategic decision making at the board level and has played an important role in making entomo a profitable business. They bring in the domain knowledge and experience while offering guidance that is right for our organisation and to the problem at hand. The guidance officered is not just in strategy, but also in network, operations, and more, while ensuring the founding team has the freedom to make independent decisions. Vickers shares the passion that entomo has towards building solutions that transform people and businesses.

As Vickers has the expertise in guiding and mentoring a spectrum of technology companies and startups to succeed, their guidance and mentoring are always timely and relevant to stage of growth the company is at. Vickers has played a key role in many instances where their support and insights have helped entomo succeed. An example of this is how Vickers had backed entomo during the testing times of the pandemic where the market came to a standstill in a matter of weeks, but Vickers showed strong trust in our ability to turn around and come out victorious which we eventually did with the business growing substantially during and post-COVID.

—Ravee Ramamoothie, Founder and Group CEO at entomo

Lumitron
Extremely-brilliant high-energy X-ray sources for medical and industrial use

Lumitron Technologies Inc. was established to develop and commercialize unique x­-ray systems that enable revolutionary new capabilities for ultra high­-fidelity imaging, ultra­-low dose radiography, hyper­-precision radiotherapy, as well as element-specific and isotope-specific material identification, assay and imaging.

Lumitron is pioneering a new class of compact and extremely-brilliant Compton light sources with monochromatic 100 keV-class x-ray outputs, comparable to the those from modern synchrotrons, in a form factor that would fit in existing clinical treatment environments. These devices have use cases across healthcare, industrial and energy sectors. For healthcare, Lumitron's imaging system vastly enhanced resolution with significant reductions in dosage enabling orders of magnitude improvement in current imaging and therapeutic modalities. The technology will enable new types of imaging and in-situ treatment such as phase-contrast imaging, precision k-edge subtraction imaging and targeted Auger-cascade therapy at the point of use. For industry, Lumitron's light sources enable unprecedented resolution in performing micron-scale, non-destructive evaluation of additively manufactured high value parts. They also enable nuclear fuel evaluation and reprocessing, a grand challenge in the nuclear energy industry that has the potential to improve nuclear security and economics of nuclear power generation. Lumitron utilizes proprietary x-ray and laser technology conceived and developed at the Lawrence Livermore National Laboratory (LLNL) by Prof Chris Barty, CTO of Lumitron and former CTO of LLNL's Laser Ignition Facility. Lumitron holds exclusive commercial development rights to these technologies.
TEAM MEMBERS
Chris Barty Ph.D., Executive Director / CTO
Maurie Stang, Executive Chairman
This is some text inside of a div block.

Vickers has been a fantastic partner.  Their involvement feels more like an inside part of the company than an outsider investor.

Vickers has been a fantastic partner.  Their involvement feels more like an inside part of the company than an outsider investor.  As a co-founder, I found it very refreshing the level of technical and financial due diligence that Vickers did prior to making their investment.  They were by far the most thorough investor in this regard. They have been proactive with the development of financial models around the growth of the company and provided insight into a range of financial vehicles that may be used at various stages of the company’s growth. 

They have also provided sound guidance with respect to the evolution of activities and access to their investor network through the annual portfolio company reviews. In particular, Xinhong Lim and Petros Farah have been involved on a weekly basis with respect to finance and planning discussions. Their inputs and efforts have been tremendously valuable pro-bono inputs to the company.

I would add that I am extremely impressed with the breadth of the Vickers team both technically and financially and am equally impressed by the breadth and quality of the various portfolio companies supported by the Vickers funds. The entire Vickers team is both professional and a pleasure with which to interact. From what I have seen of Vicker’s portfolio companies, each has a goal of providing a positive human impact. While the technologies vary tremendously, each company has an inspiring vision. This aligns fundamentally with the vision of Lumitron Technologies where our goal is to transform the detection and treatment of disease and in doing so create the clinical platforms that will eliminate the need to ever remove a breast or a prostate again.  

— Dr. Chris Barty, Executive Director/CTO, Lumitron Technologies

RWDC
Replacing petroleum-based single used plastics with biodegradable biopolymers

RWDC Industries is on a mission to replace petroleum-derived materials with safe, sustainable alternatives.

Based in the United States and Singapore, RWDC Industries is a biotech company working in harmony with nature to produce the materials we use in our daily lives. RWDC Industries has developed advanced microbial fermentation technology that uses plant-based oils to produce PHAs (or polyhydroxyalkanoates), a family of naturally occurring bioegradable biopolymers. RWDC’s PHAs — Solon™ — is certified by TÜV Austria to be fully biodegradable in soil, water and marine conditions. Solon™-based products have been shown to degrade like plant material (cellulose) within weeks and with no toxic residue. Solon™ is an ideal material to replace petroleum-derived, single-use plastics, and as such is highly sought after by some of the world's biggest converters and consumer brand owners, such as Kimberly Clark, for applications including diapers, cutlery, cups, bags, plates, and bowls.
TEAM MEMBERS
Dr. Daniel Carraway, Co-Founder & Chief Executive Office
Roland Wee, Co-Founder and Chairman
Ryan Adolphson, Chief Operating Officer
This is some text inside of a div block.

Vickers extensive expertise combined with their deep understanding of business building has enabled us to make significant progress in our journey that would not have been possible without their involvement and support.

As CEO of RWDC Industries, I am grateful for our association as a portfolio company partner of Vickers Venture Partners. Working with Dr. Finian Tan, Dr. Xinhong Lim and the entire Vickers team has been, and continues to be a significantly positive experience for our business.

Our experience with Vickers Venture Partners involves their significant contribution beyond the actual funds they have invested.  Vicker’s expertise, association with other global investors, and their extensive technical and business knowledge has resulted in their ability to provide coaching for myself and our team, guidance with regard to our business strategy and connection with a large number of potential investors.

The Vickers team has been able to quickly understand our business and the challenges we face, and they have provided invaluable guidance and support throughout the early stages of our business development.

What really differentiates Vickers Ventures, is their commitment to our success on a personal level.  Dr. Finian Tan has worked consistently to help us achieve our goals, and has been willing to commit significant blocks of their senior leader’s time to help with specific projects.  Vickers has even enabled full-time involvement of specific key leaders from their team for full-time senior staff assignments in RWDC’s business.

Vickers extensive expertise combined with their deep understanding of business building has enabled us to make significant progress in our journey that would not have been possible without their involvement and support.  We enthusiastically recommend Vickers Ventures Partners to anyone seeking a partner who can engage and help in any stage of business.  They are a top-tier venture capital firm with a proven track record of success, and we are grateful to have had the opportunity to work with them. If you are a business owner looking for a partner to help you achieve your goals, we strongly encourage you to consider reaching out to Vickers Ventures.

—Dr. Daniel Carraway, Co-Founder and CEO

SIMO
Virtual SIM technology to connect the world

SIMO identified a common pain point for all smart device users: getting on-demand, fast, secure, reliable mobile internet connections anywhere in the world.

After years of investment in R&D to solve this consumer problem, SIMO now delivers fast, secure mobile Internet in over 135 countries worldwide via patented virtual SIM™ technology, which delivers mobile data on-demand through the best local networks for one flat rate—no hidden fees, no SIM card swapping, and no surprise data charges on your mobile bill. The company is continuing its global expansion with offices in San Francisco, Berlin and Shenzhen and global distribution through Travel partners, Ecommerce channels and over 500 retail locations. SIMO delivers a seamless Software-as-a-Service data connectivity experience. They target wireless devices such as tablets, laptops, or IoT devices that are currently unconnected or poorly connected on cellular networks.Their patented software-as-a-service technology provides customers on-demand, always-available local connectivity. Their SaaS works out-of-the-box and does not require complex and lengthy integration for device manufacturers or carriers, before generating new revenue stream. They already partnered with numerous carriers, chip makers and device manufacturers to provide limitless connections to millions of customers, and welcome new partners to work together to enable a more connected world.
TEAM MEMBERS
Jing Liu, CEO & Founder
This is some text inside of a div block.

As a founder, our journey to success is unpredictable, but Vickers partners have supported us through these tough times with strategic brainstorming, key partner introductions, and leading discussions with existing shareholders to support the company's funding needs

Vickers has always been SIMO’s supporter and believer, not just in good times but especially someone we can rely on in bad times as well. As a founder, our journey to success is unpredictable, but Vickers partners have supported us through these tough times with strategic brainstorming, key partner introductions, and leading discussions with existing shareholders to support the company's funding needs. Finian is also a super fan and supported us in many ways to guide our growth and making sure we remain focused. SIMO could not have done it without Vickers’ contribution and guidance, they are one of our best investors and board members. We’re glad to be part of the Vickers’ family.

—Jing Liu, CEO of SIMO

Sisaf
Non-viral RNA Delivery and Therapeutics

SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.

Sisaf has develoepd a platform of next-generation silicon stabilized hybrid Lipid Nanoparticles (sshLNP) that can address the challenges of RNA delivery by improving the stability, safety, targeting and efficiency. Their technology broadens the potential of RNA therapeutics and also increases assesibillity to these drugs. Leveraging their technology, SiSaf is advancing a first-in-class pipeline of RNA therapeutics for rare and currently incurable autosomal dominant diseases of the bone and eye, alongside partnering with others to maximise the value Bio-Courier technology brings to RNA therapeutics and vaccines.
TEAM MEMBERS
Dr Suzanne Saffie-Siebert, Chairwoman & Chief Executive Officer
Richard Scarrott, Chief Financial Officer
This is some text inside of a div block.

Vickers was among the first to recognize the enormous potential of SiSaf’s technology. And since they understand the specific requirements of Biotech R&D, I have been able to rely on their consistent support, not only as a lead investor in several funding rounds but also as active board members.

Vickers has been instrumental in growing SiSaf from a start-up to a commercial-stage company that is now at the forefront of RNA delivery innovation. Vickers was among the first to recognize the enormous potential of SiSaf’s technology. And since they understand the specific requirements of Biotech R&D, I have been able to rely on their consistent support, not only as a lead investor in several funding rounds but also as active board members.

In 2019, before Covid vaccines demonstrated the power of RNA-based medicines, I made the strategic decision to focus the company’s R&D on RNA delivery and therapies. While some considered this a risky bet, Vickers backed my decision unreservedly This demonstrated their foresight as this strategic pivot resulted in a significant increase in SiSaf’s value. This is just one example of how Vickers supported my vision and the company’s progress.

—Dr Suzanne Saffie-Siebert, Founder & CEO, SiSaf Ltd

Spark Systems
Next generation Foreign Exchange (“FX”) trading technology solution for buyside firms

Spark Systems is a next generation Foreign Exchange trading technology solution for buyside firms.

Spark Systems incorporates cutting edge systems design and technology to gain efficient access to FX liquidity and reduce trading cost. Spark provides a liquidity aggregation platform for “buy-sides” and corporates to access liquidity from Liquidity Providers and an Electronic Communications Network that allows matching of buyside liquidity. They operate on a software as a service model.
TEAM MEMBERS
Woo Joo Seng, Founder & Chief Executive Officer
This is some text inside of a div block.

They guide, advice and counsel when the need arises and most importantly help give clarity in the myriad areas of growing world-class companies; like team composition, go to market strategies, introductions to both potential clients as well as strategic sources of funding should the need arise.

Vickers Venture is more than an investor. They are a business partner and literally have become a member of the core team. While many VCs often say that they offer more than money, sadly most do very little beyond funding a company.

Vickers talks the talk and walks the walk. They have incredible extensive networks of relationships and willingly open all these up to the companies in their portfolio. They guide, advice and counsel when the need arises and most importantly help give clarity in the myriad areas of growing world-class companies; like team composition, go to market strategies, introductions to both potential clients as well as strategic sources of funding should the need arise. This is because they know the space, they have been there and done it before and they been overwhelmingly successful at it!

—Joo Seng Wong, Founder & CEO, Sparks Systems and Co-founder, M-DAQ

Vickers Successful Exits

COMPANY
EXIT
ABOUT
Full
The Asian Food Channel (AFC) is the first and only regional Asian food TV channel. AFC has established a leadership position, not just as the only food channel, but as the leading lifestyle channel and a promoter of pan-Asian culture across the region
Full
The investment manager of Cambridge Industrial Trust (CIT), the first independent real estate investment trust (REIT) to be listed on the Stock Exchange of Singapore (SGX).
Full
Leader in high performance network security solutions.
Partial
Jing-Jin Electric (JJE) develops and manufactures high-performance electric motor systems and electric drive components 
Partial
M-DAQ builds over-the-top (OTT) applications to facilitate cross-border business for various industries. M-DAQ achieves this through their proprietary data technology and support from ⅔ of the world’s foreign exchange providers
Partial
Online platform for publishing, distribution and monetization of online games across devices spanning PC, tablets and mobile.
Full
Real Time Gaming Asia (RTG Asia) is the master licensor of standard random-number-generated (RNG) casino games in the Asian region, primarily in the Philippines.
Full
TWG Tea is a luxury concept that incorporates an international distribution network to professionals, unique and original retail outlets and exquisite tea rooms.
Full
UUCun is one of the leading performance-based mobile advertisement networks in China. UUCun provides a platform for their customers to distribute advertisements to different mobile media distributors and shares advertising revenues with them.